Stockscreener 앱 받기
6.3549
1.93%
-0.1051
Scilex Holding Company 주식(SCLX)의 최신 뉴스
Why Scilex Holding Company stock attracts strong analyst attentionHigh Return Setup Scanner - beatles.ru
Even With A 27% Surge, Cautious Investors Are Not Rewarding Scilex Holding Company's (NASDAQ:SCLX) Performance Completely - simplywall.st
SCLX registers 1.594M shares & 1.403M warrants; directors re-elected | SCLXW SEC FilingForm 424B3 - Stock Titan
Scilex Holding Company Concludes 2025 Annual Stockholders Meeting - TipRanks
Scilex (SCLX) Board defers dividend record date; uncertainty remains | MGIH SEC FilingForm 6-K - Stock Titan
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - The Manila Times
Scilex reports publication on Gloperba dosing adjustments - TipRanks
Scilex announces dosing guide for gout medication GLOPERBA - Investing.com
Scilex Postpones Annual Meeting Due to Quorum Issue - TipRanks
Scilex (NASDAQ:SCLX) Stock Price Down 2.8% – What’s Next? - Defense World
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - The Manila Times
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL - GlobeNewswire Inc.
New Non-Opioid Pain Treatment SP-102 Demonstrates Superior Efficacy in Latest Clinical Analysis - Stock Titan
Scilex Holding 2025 Q1 Earnings Misses Targets as Net Income Worsens by 7% - AInvest
Scilex Bio signs binding term sheet with NeuroBiogen - TipRanks
Scilex Updates Director Compensation Following Stock Split - TipRanks
Scilex adjusts director compensation post-stock split - Investing.com
Scilex (SCLX) Expected to Announce Quarterly Earnings on Monday - Defense World
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - GlobeNewswire
New Clinical Data: Scilex's Non-Opioid SP-102 Shows Promising Results for Chronic Back Pain Treatment - Stock Titan
Scilex Regains Compliance With Nasdaq Listing Rule; Shares Rise - marketscreener.com
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire
Scilex Holding Company’s Market Journey: Closing Weak at 0.24, Down -2.01 - DWinneX
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces New Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - The Manila Times
Scilex Holding Company Announces Change in Record Date for - GlobeNewswire
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - Yahoo Finance
Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com Canada
Scilex Holding Amends Merger Agreement with Denali - Investing.com Australia
SCLX stock touches 52-week low at $5.8 amid market challenges - Investing.com
Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 - Seeking Alpha
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - The Manila Times
Scilex Gets FDA Orphan Drug Label for Colchicine for Pericarditis - marketscreener.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine - marketscreener.com
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire
Scilex Holding announces 1-for-35 reverse stock split By Investing.com - Investing.com Canada
What Does the Market Think About Scilex Holding?Scilex Holding (NASDAQ:SCLX) - Benzinga
Scilex Holding announces 1-for-35 reverse stock split - Investing.com Australia
Canada approves Scilex’s migraine solution ELYXYB - Investing.com
Scilex Holding Company Announces Approval of a New Drug - GlobeNewswire
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Witho - Yahoo Finance
Canada approves Scilex’s migraine solution ELYXYB By Investing.com - Investing.com UK
Scilex’s (SCLX) Hold Rating Reiterated at D. Boral Capital - Defense World
Scilex downgraded to Hold from Buy at D. Boral Capital - Yahoo Finance
Scilex's Strategic Crossroads: Downgrade Highlights High Stakes in Biotech's Volatile Landscape - AInvest
Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules - Investing.com Nigeria
Scilex to Implement 1-for-35 Reverse Stock Split - marketscreener.com
Scilex Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks
Scilex Holding Company Announces 1-For-35 Reverse Stock Split - marketscreener.com
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire
D. Boral Capital Cuts Scilex (NASDAQ:SCLX) Price Target to $18.00 - The AM Reporter
D. Boral Capital Has Lowered Expectations for Scilex (NASDAQ:SCLX) Stock Price - Defense World
Is Scilex Holding Company (NASDAQ: SCLX) Still A Good Investment? - stocksregister.com
Scilex Holding Company (SCLX) reports earnings - qz.com
0.11%
1.70%
자본화:
|
볼륨(24시간):